Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01380535

Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)

Chronic Graft Versus Host Disease Clinical Trial

Official title:
A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy With UVADEX for the Treatment of Patients With Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD)

Clinical Trial Summary

Chronic graft-versus-host disease (cGVHD) is a long-lasting complication that can occur after transplants. The transplanted cells seem to fight with the patient's own cells.

Extracorporeal photopheresis (ECP) is a fairly new procedure for cGVHD. The participant gets a port to hook up to a machine. The machine removes the white blood cells, mixes them with a light-sensitive drug, shines light on it, and puts all the blood back in.

This study will find out if patients respond better if they get ECP with methoxsalen, in addition to the pills normally used to treat cGVHD.

Clinical Trial Description

The investigation of extracorporeal photopheresis (ECP) plus standard of care (SoC) (SoC+ECP) in chronic graft-versus-host disease (cGVHD) within prospective, randomized clinical studies is limited, despite its frequent clinical use.

This phase 1/pilot study was the first randomized, prospective study to investigate ECP use as first-line therapy in cGVHD, based on the 2015 National Institutes of Health (NIH) consensus criteria for diagnosis and response assessment.

Adult patients with new-onset (≤3 years of hematopoietic stem cell transplantation) moderate or severe cGVHD were randomized 1:1 to 26 weeks of SoC+ECP vs SoC (corticosteroids and cyclosporine A/tacrolimus) between 2011 and 2015. The primary endpoint was overall response rate (ORR), defined as complete or partial response, at week 28 in the intention-to-treat population (ITT). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01380535
Study type Interventional
Source Mallinckrodt
Contact
Status Completed
Phase Early Phase 1
Start date November 2011
Completion date March 2015
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Terminated NCT02337517 - Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease Phase 2
Terminated NCT02461134 - Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD Phase 2
Recruiting NCT03839069 - Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis N/A
Active, not recruiting NCT00637689 - Improving Outcomes Assessment in Chronic GVHD
Active, not recruiting NCT01937468 - Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease Phase 1
Completed NCT01810718 - Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD Phase 1
Terminated NCT01964625 - Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD) N/A
Active, not recruiting NCT03790332 - Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD) Phase 1/Phase 2
Completed NCT01680965 - Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Phase 1/Phase 2
Completed NCT02491359 - Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease Phase 2
Terminated NCT02701634 - Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD) Phase 2
Recruiting NCT05567406 - Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy Phase 2
Active, not recruiting NCT04212416 - Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease Phase 1
Completed NCT02959944 - Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) Phase 3
Not yet recruiting NCT06271616 - Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant Phase 2
Completed NCT01954979 - Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD) Phase 1
Active, not recruiting NCT04640025 - A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib Phase 2
Completed NCT03483675 - Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease Phase 2
Recruiting NCT04431479 - Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study